5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
start O
Enbrel O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
and O
stop O
Enbrel O
if O
infection O
becomes O
serious O
. O

( O
5.1 O
) O
* O
Consider O
empiric O
anti-fungal O
therapy O
for O
patients O
at O
risk O
for O
invasive O
fungal O
infections O
who O
develop O
a O
severe O
systemic O
illness O
on O
Enbrel O
( O
those O
who O
reside O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
) O
. O

( O
5.1 O
) O
* O
Demyelinating O
disease O
, O
exacerbation O
or O
new O
onset O
, O
may O
occur O
. O

( O
5.2 O
) O
* O
Cases O
of O
lymphoma O
have O
been O
observed O
in O
patients O
receiving O
TNF-blocking O
agents O
. O

( O
5.3 O
) O
* O
Congestive O
heart O
failure O
, O
worsening O
or O
new O
onset O
, O
may O
occur O
. O

( O
5.4 O
) O
* O
Advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
symptoms O
of O
pancytopenia O
or O
aplastic O
anemia O
develop O
, O
and O
consider O
stopping O
Enbrel O
. O

( O
5.5 O
) O
* O
Monitor O
patients O
previously O
infected O
with O
hepatitis O
B O
virus O
for O
reactivation O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
consider O
stopping O
Enbrel O
and O
beginning O
anti-viral O
therapy O
. O

( O
5.6 O
) O
* O
Anaphylaxis O
or O
serious O
allergic O
reactions O
may O
occur O
. O

( O
5.7 O
) O
* O
Stop O
Enbrel O
if O
lupus-like O
syndrome O
or O
autoimmune O
hepatitis O
develops O
. O

( O
5.9 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
Enbrel O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacterial O
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
parasitic O
, O
or O
other O
opportunistic O
pathogens O
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

Treatment O
with O
Enbrel O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
infection B-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
, O
and/or O
patients O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
( O
such O
as O
corticosteroids O
or O
methotrexate O
) O
, O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
: O
* O
With O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
Who O
have O
been O
exposed O
to O
tuberculosis B-Not_AE_Candidate
; O
* O
With O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
Who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic O
mycoses B-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
With O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
such O
as O
advanced O
or O
poorly O
controlled O
diabetes B-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
Enbrel O
. O

Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-OSE_Labeled_AE
during O
treatment O
with O
Enbrel O
should O
be O
closely O
monitored O
, O
undergo O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-NonOSE_AE
patient O
, O
and O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
Enbrel O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-NonOSE_AE
or O
active O
tuberculosis I-NonOSE_AE
. O

Data O
from O
clinical O
trials O
and O
preclinical O
studies O
suggest O
that O
the O
risk O
of O
reactivation B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
is O
lower O
with O
Enbrel O
than O
with O
TNF-blocking O
monoclonal O
antibodies O
. O

Nonetheless O
, O
postmarketing O
cases O
of O
tuberculosis B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
have O
been O
reported O
for O
TNF O
blockers O
, O
including O
Enbrel O
. O

Tuberculosis B-OSE_Labeled_AE
has O
developed O
in O
patients O
who O
tested O
negative B-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
prior O
to O
initiation O
of O
therapy O
. O

Patients O
should O
be O
evaluated O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
tested O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
Enbrel O
and O
periodically O
during O
therapy O
. O

Tests B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
falsely I-NonOSE_AE
negative I-NonOSE_AE
while O
on O
therapy O
with O
Enbrel O
. O

Treatment O
of O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
therapy O
with O
TNF-blocking O
agents O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Induration B-NonOSE_AE
of I-NonOSE_AE
5 I-NonOSE_AE
mm I-NonOSE_AE
or I-NonOSE_AE
greater I-NonOSE_AE
with I-NonOSE_AE
tuberculin I-NonOSE_AE
skin I-NonOSE_AE
testing I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
considered I-NonOSE_AE
a I-NonOSE_AE
positive I-NonOSE_AE
test I-NonOSE_AE
result O
when O
assessing O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
prior O
to O
initiating O
Enbrel O
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
should O
also O
be O
considered O
prior O
to O
initiation O
of O
Enbrel O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
is O
appropriate O
for O
an O
individual O
patient O
. O

Tuberculosis B-NonOSE_AE
should O
be O
strongly O
considered O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
Enbrel O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

Invasive O
Fungal O
Infections O
Cases O
of O
serious O
and O
sometimes O
fatal B-NonOSE_AE
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

For O
patients O
who O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
should O
be O
suspected O
if O
they O
develop O
a O
serious O
systemic B-NonOSE_AE
illness I-NonOSE_AE
. O

Appropriate O
empiric O
anti-fungal O
therapy O
should O
be O
considered O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

When O
feasible O
, O
the O
decision O
to O
administer O
empiric O
anti-fungal O
therapy O
in O
these O
patients O
should O
be O
made O
in O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive O
fungal B-NonOSE_AE
infections I-NonOSE_AE
and O
should O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
anti-fungal O
therapy O
. O

In O
38 O
Enbrel O
clinical O
trials O
and O
4 O
cohort O
studies O
in O
all O
approved O
indications O
representing O
27,169 O
patient-years O
of O
exposure O
( O
17,696 O
patients O
) O
from O
the O
United O
States O
and O
Canada O
, O
no O
histoplasmosis B-NonOSE_AE
infections I-NonOSE_AE
were O
reported O
among O
patients O
treated O
with O
Enbrel O
. O

5.2 O
Neurologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Treatment O
with O
TNF-blocking O
agents O
, O
including O
Enbrel O
, O
has O
been O
associated O
with O
rare O
( O
< O
0.1 O
% O
) O
cases O
of O
new O
onset O
or O
exacerbation O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
some O
presenting O
with O
mental B-OSE_Labeled_AE
status I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
and O
some O
associated O
with O
permanent O
disability O
, O
and O
with O
peripheral B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
. O

Cases O
of O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
, O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
other O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
, O
and O
new O
onset O
or O
exacerbation O
of O
seizure B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
have O
been O
reported O
in O
postmarketing O
experience O
with O
Enbrel O
therapy O
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
Enbrel O
in O
patients O
with O
preexisting O
or O
recent-onset O
central O
or O
peripheral O
nervous O
system O
demyelinating B-Not_AE_Candidate
disorders I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.3 O
Malignancies O
Lymphomas O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
TNF-blocking O
agents O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
a O
TNF O
blocker O
compared O
to O
control O
patients O
. O

During O
the O
controlled O
portions O
of O
Enbrel O
trials O
in O
adult O
patients O
with O
RA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
, O
and O
PsA B-Not_AE_Candidate
, O
2 O
lymphomas B-OSE_Labeled_AE
were O
observed O
among O
3306 O
Enbrel-treated O
patients O
versus O
0 O
among O
1521 O
control O
patients O
( O
duration O
of O
controlled O
treatment O
ranged O
from O
3 O
to O
36 O
months O
) O
. O

Among O
6543 O
adult O
rheumatology O
( O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
) O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
uncontrolled O
portions O
of O
clinical O
trials O
, O
representing O
approximately O
12,845 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
lymphoma B-OSE_Labeled_AE
was O
0.10 O
cases O
per O
100 O
patient-years O
. O

This O
was O
3-fold O
higher O
than O
the O
rate O
of O
lymphoma B-NonOSE_AE
expected O
in O
the O
general O
U.S O
. O
population O
based O
on O
the O
Surveillance O
, O
Epidemiology O
, O
and O
End O
Results O
( O
SEER O
) O
Database O
. O

An O
increased O
rate O
of O
lymphoma B-NonOSE_AE
up O
to O
several-fold O
has O
been O
reported O
in O
the O
RA B-Not_AE_Candidate
patient O
population O
, O
and O
may O
be O
further O
increased O
in O
patients O
with O
more O
severe O
disease O
activity O
. O

Among O
4410 O
adult O
PsO B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
in O
clinical O
trials O
up O
to O
36 O
months O
, O
representing O
approximately O
4278 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
lymphoma B-NonOSE_AE
was O
0.05 O
cases O
per O
100 O
patient-years O
, O
which O
is O
comparable O
to O
the O
rate O
in O
the O
general O
population O
. O

No O
cases O
were O
observed O
in O
Enbrel- O
or O
placebo-treated O
patients O
during O
the O
controlled O
portions O
of O
these O
trials O
. O

Leukemia O
Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
postmarketing O
TNF-blocker O
use O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF-blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

During O
the O
controlled O
portions O
of O
Enbrel O
trials O
, O
2 O
cases O
of O
leukemia B-OSE_Labeled_AE
were O
observed O
among O
5445 O
( O
0.06 O
cases O
per O
100 O
patient-years O
) O
Enbrel-treated O
patients O
versus O
0 O
among O
2890 O
( O
0 O
% O
) O
control O
patients O
( O
duration O
of O
controlled O
treatment O
ranged O
from O
3 O
to O
48 O
months O
) O
. O

Among O
15,401 O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
open O
portions O
of O
clinical O
trials O
representing O
approximately O
23,325 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
leukemia B-OSE_Labeled_AE
was O
0.03 O
cases O
per O
100 O
patient-years O
. O

Other O
Malignancies O
Information O
is O
available O
from O
10,953 O
adult O
patients O
with O
17,123 O
patient-years O
and O
696 O
pediatric O
patients O
with O
1282 O
patient-years O
of O
experience O
across O
45 O
Enbrel O
clinical O
studies O
. O

For O
malignancies B-NonOSE_AE
other O
than O
lymphoma B-NonOSE_AE
and O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
, O
there O
was O
no O
difference O
in O
exposure-adjusted O
rates O
between O
the O
Enbrel O
and O
control O
arms O
in O
the O
controlled O
portions O
of O
clinical O
studies O
for O
all O
indications O
. O

Analysis O
of O
the O
malignancy B-NonOSE_AE
rate O
in O
combined O
controlled O
and O
uncontrolled O
portions O
of O
studies O
has O
demonstrated O
that O
types O
and O
rates O
are O
similar O
to O
what O
is O
expected O
in O
the O
general O
U.S O
. O
population O
based O
on O
the O
SEER O
database O
and O
suggests O
no O
increase O
in O
rates O
over O
time O
. O

Whether O
treatment O
with O
Enbrel O
might O
influence O
the O
development O
and O
course O
of O
malignancies B-NonOSE_AE
in O
adults O
is O
unknown O
. O

Melanoma O
and O
Non O
- O
M O
elanoma O
S O
kin O
C O
ancer O
( O
NMSC O
) O
Melanoma B-OSE_Labeled_AE
and O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
TNF O
antagonists O
including O
etanercept O
. O

Among O
15,401 O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
open O
portions O
of O
clinical O
trials O
representing O
approximately O
23,325 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
melanoma B-OSE_Labeled_AE
was O
0.043 O
cases O
per O
100 O
patient-years O
. O

Among O
3306 O
adult O
rheumatology O
( O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
) O
patients O
treated O
with O
Enbrel O
in O
controlled O
clinical O
trials O
representing O
approximately O
2669 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
NMSC B-OSE_Labeled_AE
was O
0.41 O
cases O
per O
100 O
patient-years O
vs O
0.37 O
cases O
per O
100 O
patient-years O
among O
1521 O
control-treated O
patients O
representing O
1077 O
patient-years O
. O

Among O
1245 O
adult O
PsO B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
in O
controlled O
clinical O
trials O
, O
representing O
approximately O
283 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
NMSC B-OSE_Labeled_AE
was O
3.54 O
cases O
per O
100 O
patient-years O
vs O
1.28 O
cases O
per O
100 O
patient-years O
among O
720 O
control-treated O
patients O
representing O
156 O
patient-years O
. O

Postmarketing O
cases O
of O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
very O
infrequently O
in O
patients O
treated O
with O
Enbrel O
. O

Periodic O
skin O
examinations O
should O
be O
considered O
for O
all O
patients O
at O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

Pediatric O
Patients O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
, O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
at O
< O
= O
18 O
years O
of O
age O
) O
, O
including O
Enbrel O
. O

Approximately O
half O
the O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
different O
malignancies B-OSE_Labeled_AE
and O
included O
rare O
malignancies B-OSE_Labeled_AE
usually O
associated O
with O
immunosuppression B-NonOSE_AE
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
of O
therapy O
( O
range O
1 O
to O
84 O
months O
) O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants B-NonOSE_AE
. O

These O
cases O
were O
reported O
postmarketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

In O
clinical O
trials O
of O
1140 O
pediatric O
patients O
representing O
1927.2 O
patient-years O
of O
therapy O
, O
no O
malignancies B-NonOSE_AE
, O
including O
lymphoma B-NonOSE_AE
or O
NMSC B-NonOSE_AE
, O
have O
been O
reported O
. O

Post O
m O
arketing O
Use O
In O
global O
postmarketing O
adult O
and O
pediatric O
use O
, O
lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
have O
been O
reported O
. O

5.4 O
Patients O
With O
Heart O
Failure O
Two O
clinical O
trials O
evaluating O
the O
use O
of O
Enbrel O
in O
the O
treatment O
of O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
were O
terminated O
early O
due O
to O
lack O
of O
efficacy O
. O

One O
of O
these O
studies O
suggested O
higher O
mortality B-NonOSE_AE
in O
Enbrel-treated O
patients O
compared O
to O
placebo O
[ O
see O
Adverse O
React O
ion O
s O
( O
6.2 O
) O
] O
. O

There O
have O
been O
postmarketing O
reports O
of O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
) O
, O
with O
and O
without O
identifiable O
precipitating O
factors O
, O
in O
patients O
taking O
Enbrel O
. O

There O
have O
also O
been O
rare O
( O
< O
0.1 O
% O
) O
reports O
of O
new B-OSE_Labeled_AE
onset I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
, O
including O
CHF B-OSE_Labeled_AE
in O
patients O
without O
known O
preexisting O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Some O
of O
these O
patients O
have O
been O
under O
50 O
years O
of O
age O
. O

Physicians O
should O
exercise O
caution O
when O
using O
Enbrel O
in O
patients O
who O
also O
have O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
monitor O
patients O
carefully O
. O

5.5 O
Hematologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Rare O
( O
< O
0.1 O
% O
) O
reports O
of O
pancytopenia B-OSE_Labeled_AE
, O
including O
very O
rare O
( O
< O
0.01 O
% O
) O
reports O
of O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
treated O
with O
Enbrel O
. O

The O
causal O
relationship O
to O
Enbrel O
therapy O
remains O
unclear O
. O

Although O
no O
high-risk O
group O
has O
been O
identified O
, O
caution O
should O
be O
exercised O
in O
patients O
being O
treated O
with O
Enbrel O
who O
have O
a O
previous O
history O
of O
significant O
hematologic B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
. O

All O
patients O
should O
be O
advised O
to O
seek O
immediate O
medical O
attention O
if O
they O
develop O
signs O
and O
symptoms O
suggestive O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
or O
infection B-NonOSE_AE
( O
eg O
, O
persistent B-NonOSE_AE
fever I-NonOSE_AE
, O
bruising B-NonOSE_AE
, O
bleeding B-NonOSE_AE
, O
pallor B-NonOSE_AE
) O
while O
on O
Enbrel O
. O

Discontinuation O
of O
Enbrel O
therapy O
should O
be O
considered O
in O
patients O
with O
confirmed O
significant O
hematologic B-NonOSE_AE
abnormalities I-NonOSE_AE
. O

Two O
percent O
of O
patients O
treated O
concurrently O
with O
Enbrel O
and O
anakinra O
developed O
neutropenia B-NonOSE_AE
( O
ANC B-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
) O
. O

While O
neutropenic B-NonOSE_AE
, O
one O
patient O
developed O
cellulitis B-NonOSE_AE
that O
resolved O
with O
antibiotic O
therapy O
. O

5.6 O
Hepatitis O
B O
Reactivation O
Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
in O
patients O
who O
were O
previously O
infected B-Not_AE_Candidate
with I-Not_AE_Candidate
the I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
virus I-Not_AE_Candidate
( I-Not_AE_Candidate
HBV I-Not_AE_Candidate
) O
and O
had O
received O
concomitant O
TNF-blocking O
agents O
, O
including O
very O
rare O
cases O
( O
< O
0.01 O
% O
) O
with O
Enbrel O
, O
has O
been O
reported O
. O

In O
some O
instances O
, O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
occurring O
in O
conjunction O
with O
TNF-blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
concomitantly O
receiving O
other O
medications B-NonOSE_AE
that I-NonOSE_AE
suppress I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
, O
which O
may O
also O
contribute O
to O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
at O
risk O
for O
HBV B-NonOSE_AE
infection I-NonOSE_AE
should O
be O
evaluated O
for O
prior O
evidence O
of O
HBV B-NonOSE_AE
infection I-NonOSE_AE
before O
initiating O
TNF-blocker O
therapy O
. O

Prescribers O
should O
exercise O
caution O
in O
prescribing O
TNF O
blockers O
in O
patients O
previously O
infected O
with O
HBV B-Not_AE_Candidate
. O

Adequate O
data O
are O
not O
available O
on O
the O
safety O
or O
efficacy O
of O
treating O
patients O
who O
are O
carriers O
of O
HBV B-NonOSE_AE
with O
anti-viral O
therapy O
in O
conjunction O
with O
TNF-blocker O
therapy O
to O
prevent O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
previously O
infected O
with O
HBV B-Not_AE_Candidate
and O
requiring O
treatment O
with O
Enbrel O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active B-NonOSE_AE
HBV I-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
consideration O
should O
be O
given O
to O
stopping O
Enbrel O
and O
initiating O
anti-viral O
therapy O
with O
appropriate O
supportive O
treatment O
. O

The O
safety O
of O
resuming O
Enbrel O
therapy O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
weigh O
the O
risks O
and O
benefits O
when O
considering O
resumption O
of O
therapy O
in O
this O
situation O
. O

5.7 O
Allergic O
Reactions O
Allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
associated O
with O
administration O
of O
Enbrel O
during O
clinical O
trials O
have O
been O
reported O
in O
< O
2 O
% O
of O
patients O
. O

If O
an O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
or O
other O
serious O
allergic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
Enbrel O
should O
be O
discontinued O
immediately O
and O
appropriate O
therapy O
initiated O
. O

Caution O
: O
The O
following O
components O
contain O
dry O
natural O
rubber O
( O
a O
derivative O
of O
latex O
) O
, O
which O
may O
cause O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
individuals O
sensitive O
to O
latex I-OSE_Labeled_AE
: O
the O
needle O
cover O
of O
the O
prefilled O
syringe O
, O
the O
needle O
cover O
within O
the O
white O
cap O
of O
the O
SureClick O
autoinjector O
, O
and O
the O
needle O
cover O
within O
the O
purple O
cap O
of O
the O
Enbrel O
Mini O
cartridge O
. O

5.8 O
Immunizations O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
Enbrel O
. O

It O
is O
recommended O
that O
pediatric O
patients O
, O
if O
possible O
, O
be O
brought O
up-to-date O
with O
all O
immunizations O
in O
agreement O
with O
current O
immunization O
guidelines O
prior O
to O
initiating O
Enbrel O
therapy O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.9 O
Autoimmunity O
Treatment O
with O
Enbrel O
may O
result O
in O
the O
formation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
autoantibodies I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
and O
, O
rarely O
( O
< O
0.1 O
% O
) O
, O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
, O
which O
may O
resolve O
following O
withdrawal O
of O
Enbrel O
. O

If O
a O
patient O
develops O
symptoms O
and O
findings O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
or O
autoimmune B-NonOSE_AE
hepatitis I-NonOSE_AE
following O
treatment O
with O
Enbrel O
, O
treatment O
should O
be O
discontinued O
and O
the O
patient O
should O
be O
carefully O
evaluated O
. O

5.10 O
Immunosuppression O
TNF O
mediates O
inflammation B-NonOSE_AE
and O
modulates B-NonOSE_AE
cellular I-NonOSE_AE
immune I-NonOSE_AE
responses O
. O

TNF-blocking O
agents O
, O
including O
Enbrel O
, O
affect O
host O
defenses O
against O
infections B-NonOSE_AE
. O

The O
effect O
of O
TNF O
inhibition O
on O
the O
development O
and O
course O
of O
malignancies B-NonOSE_AE
is O
not O
fully O
understood O
. O

In O
a O
study O
of O
49 O
patients O
with O
RA B-Not_AE_Candidate
treated O
with O
Enbrel O
, O
there O
was O
no O
evidence O
of O
depression B-NonOSE_AE
of I-NonOSE_AE
delayed I-NonOSE_AE
- I-NonOSE_AE
type I-NonOSE_AE
hypersensitivity I-NonOSE_AE
, O
depression B-NonOSE_AE
of I-NonOSE_AE
immunoglobulin I-NonOSE_AE
levels I-NonOSE_AE
, O
or O
change B-NonOSE_AE
in I-NonOSE_AE
enumeration I-NonOSE_AE
of I-NonOSE_AE
effector I-NonOSE_AE
cell I-NonOSE_AE
populations I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Use O
in O
Wegener O
's O
Granulomatosis O
Patients O
The O
use O
of O
Enbrel O
in O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
receiving O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
is O
not O
recommended O
. O

In O
a O
study O
of O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
, O
the O
addition O
of O
Enbrel O
to O
standard O
therapy O
( O
including O
cyclophosphamide O
) O
was O
associated O
with O
a O
higher O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
solid I-NonOSE_AE
malignancies I-NonOSE_AE
and O
was O
not O
associated O
with O
improved O
clinical O
outcomes O
when O
compared O
with O
standard O
therapy O
alone O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.12 O
Use O
with O
Anakinra O
or O
Abatacept O
Use O
of O
Enbrel O
with O
anakinra O
or O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.13 O
Use O
in O
Patients O
with O
Moderate O
to O
Severe O
Alcoholic O
Hepatitis O
In O
a O
study O
of O
48 O
hospitalized O
patients O
treated O
with O
Enbrel O
or O
placebo O
for O
moderate O
to O
severe O
alcoholic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
, O
the O
mortality B-NonOSE_AE
rate O
in O
patients O
treated O
with O
Enbrel O
was O
similar O
to O
patients O
treated O
with O
placebo O
at O
1 O
month O
but O
significantly O
higher O
after O
6 O
months O
. O

Physicians O
should O
use O
caution O
when O
using O
Enbrel O
in O
patients O
with O
moderate O
to O
severe O
alcoholic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
. O

